A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...
Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss ...
The company states: “Novo Nordisk (NVO) announced headline results ... demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo.
Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...
Novo Nordisk's shares surged by 8.1% on Friday following the announcement of promising clinical trial results for their innovative weight loss medication, Amycretin.
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback